Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA HIV-C
- Development stage
- Phase 2
- Lead developer
- EuroVacc Foundation
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
DNA HIV-C is an investigational prophylactic DNA vaccine developed by the EuroVacc Foundation for the prevention of HIV-1 infection. It is specifically designed based on the HIV-1 subtype C (clade C) CN54 strain, which is the dominant strain in China, India, and sub-Saharan Africa. The vaccine consists of a plasmid DNA encoding two primary antigens: an artificial 160-kDa GagPolNef (GPN) polyprotein and the external glycoprotein gp120, both of which are codon-optimized for expression in human cells. In clinical development, DNA HIV-C has been evaluated as a priming agent in heterologous prime-boost regimens, typically followed by a viral vector boost such as NYVAC-HIV-C, to induce robust HIV-specific cell-mediated immune responses, including CD4+ and CD8+ T cells.
- Other names
- DNA-C vaccineEuroVacc DNA vaccineEuroVacc DNA-C
02
Targets
TLR9 (Toll-like receptor 9)Env (HIV-1 envelope glycoprotein)Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on DNA HIV-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA HIV-C.